NeuroSense Therapeutics Ltd. NRSN

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) provided a H1 2026 business update, outlining a capital-efficient plan to push PrimeC for ALS toward late-stage development. PARADIGM Phase 2b results were published in JAMA Neurology in March 2026, with long-term data showing a 65% reduction in mortality risk and a median survival of 36.3 months for PrimeC-treated patients; June 2026 also saw PARADIGM meet its primary endpoint, reducing extracellular vesicle–associated TDP-43 versus placebo. Canada advanced toward an NDS filing, targeting December 2026, after Pre-NDS alignment with Health Canada. In the U.S., NeuroSense is pursuing an optimized strategy, including AI-enabled formulation characterization, a planned active-comparator trial against edaravone, and a potentially smaller pivotal PARAGON design, while FDA discussions assess potential full approval or Accelerated Approval paths. Financing and strategic options remain a priority. H1 2026 expenses fell versus 2025 (R&D $2.102M, G&A $1.345M); net loss $3.563M; cash and cash equivalents about $0.231M. Positive Phase 2b results and regulatory progress create a milestone-driven, capital-efficient path that could significantly influence PrimeC's development and investor sentiment.

NeuroSense Therapeutics Ltd. reveals an accelerated and capital-efficient plan to progress PrimeC towards possible approval for treating ALS. Strategy announcement accelerates PrimeC development toward ALS approval and could significantly alter company trajectory and investor sentiment.

NeuroSense Therapeutics completes PrimeC pre-NDS process and advances toward December 2026 filing with Health Canada. Regulatory step for PrimeC marks pipeline progress but filing date remains distant.

NeuroSense Therapeutics advances PrimeC toward new drug submission to Health Canada for ALS treatment. PrimeC advancement toward Health Canada submission signals key regulatory milestone for NeuroSense's ALS therapy.

NeuroSense Therapeutics CEO Alon Ben-Noon will join actor and ALS advocate Aaron Lazar for a live podcast discussing ALS science, PrimeC's commercialization strategies, and regulatory progress in Canada. The event, scheduled for August 4, 2025, will allow audience interaction through live questions. Lazar, diagnosed with ALS, aims to raise awareness and share insights on NeuroSense's investigational therapy, PrimeC, which has shown promise in altering ALS progression. The session targets the ALS community, media, and biotech investors. The live podcast highlights significant developments in ALS treatment and regulatory progress, which could influence investor sentiment and the company's market trajectory.

NeuroSense Therapeutics Ltd. achieved primary endpoint in Phase 2b ALS study with statistically significant reduction of TDP-43. Positive Phase 2b ALS results with TDP-43 reduction represent major clinical milestone likely to drive further development and investor interest.

NeuroSense Therapeutics reports positive biomarker findings from Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer's disease. Positive Phase 2 biomarker data for PrimeC advances Alzheimer's pipeline with potential to shift company trajectory.

NeuroSense Therapeutics Ltd. has been granted a South Korean patent covering PrimeC composition for ALS treatment. South Korean patent grant adds intellectual property protection for PrimeC in an additional key market, supporting potential future commercialization.

NeuroSense Therapeutics Ltd. receives Japanese patent grant for PrimeC novel composition targeting neurodegenerative diseases such as ALS. Japanese patent grant strengthens PrimeC intellectual property in one market but delivers only incremental rather than transformative progress.

NeuroSense Therapeutics Ltd. (NRSN) announced the pricing of an insider-led PIPE financing, securing capital investment from company insiders to support operations. Insider-led PIPE financing delivers immediate capital and conveys strong management confidence, significantly enhancing NRSN's liquidity and investor sentiment.

NeuroSense Therapeutics Ltd. (NRSN) received a Brazilian patent for the PrimeC composition, bolstering its intellectual property for the ALS therapy targeting neurodegeneration. Brazilian patent for PrimeC fortifies NeuroSense's IP portfolio, enabling market expansion and competitive edge in ALS treatment.

NeuroSense Therapeutics Ltd. (NRSN) received Nasdaq notifications for failing to meet the minimum bid price requirement of $1.00 for 30 consecutive business days and the market value of listed securities requirement of $35 million for 30 consecutive business days. Nasdaq non-compliance notifications for bid price and market value requirements threaten NRSN's listing status, eroding investor confidence and stock performance.

NeuroSense Therapeutics Ltd. (NRSN) reported year-end 2025 financial results and provided a business update. Year-end financial results and business updates provide key insights into clinical progress and cash runway, moderately influencing NRSN's trajectory and investor sentiment.

NeuroSense Therapeutics Ltd. (NRSN) advances toward key regulatory milestones with a strengthened data package and near-term Alzheimer's readout. Progress toward regulatory milestones with strengthened data and near-term Alzheimer's readout represents a major strategic advancement for NRSN's pipeline and investor sentiment.

NeuroSense Therapeutics Ltd. (NRSN) announces new data on PrimeC for presentation at the AD/PD™ 2026 Conference. Presentation of new PrimeC data at the premier AD/PD™ 2026 Conference boosts NRSN's visibility and credibility in neurodegenerative therapeutics.

JAMA Neurology published results from NeuroSense Therapeutics' PARADIGM Phase 2b trial of PrimeC for ALS, demonstrating meaningful clinical outcomes and biological activity. Positive Phase 2b trial results for PrimeC in ALS published in JAMA Neurology mark a major clinical milestone likely to drive NeuroSense's development pipeline forward and boost investor sentiment.

NeuroSense Therapeutics Ltd. (NRSN) will present long-term survival data from its PrimeC ALS therapy at a leading scientific conference. Presentation of long-term survival data for lead ALS candidate PrimeC at a major conference signals key clinical progress likely to boost investor sentiment and stock trajectory.

NeuroSense Therapeutics Ltd. (NRSN) announces statistically significant 65% reduction in risk of death and greater than 14-month median survival benefit with PrimeC in ALS. PrimeC's ALS survival data represents a potential breakthrough therapy that could secure FDA approval, partnerships, and explosive stock growth for NeuroSense.

NeuroSense Therapeutics Ltd. has secured a granted patent in Australia for its PrimeC composition, enhancing its global intellectual property protection strategy. This patent is expected to bolster the company's position in the market as it continues to develop treatments for neurodegenerative diseases. The granted patent significantly strengthens NeuroSense's competitive position and could lead to major advancements in product development and market presence.

NeuroSense Therapeutics Ltd. has been granted a U.S. patent for a novel treatment aimed at Alzheimer's disease. This patent is expected to enhance the company's position in the competitive landscape of Alzheimer's therapies, potentially leading to new opportunities for development and commercialization. The patent covers a unique approach that may improve patient outcomes and aligns with the growing demand for effective Alzheimer's treatments. The patent grant represents a significant strategic advancement that could enhance NeuroSense's market position and investor sentiment.

NeuroSense Therapeutics Ltd. has appointed Prof. Steven Arnold, a renowned expert in Alzheimer's disease, to its Scientific Advisory Board (SAB). Prof. Arnold's extensive experience and research in neurodegenerative diseases are expected to enhance the company's strategic direction and innovation in developing treatments for Alzheimer's. His involvement is anticipated to strengthen NeuroSense's credibility and potentially improve its market position in the competitive landscape of Alzheimer's therapeutics. The addition of a prominent Alzheimer's expert to the SAB is likely to significantly influence NeuroSense's strategic direction and enhance its credibility in the market.

NeuroSense Therapeutics Ltd. announced positive results from its Phase 2 study of PrimeC, demonstrating favorable safety and tolerability in Alzheimer's patients. The study's outcomes support the continued development of PrimeC as a potential treatment for the disease, highlighting its promise in addressing Alzheimer's-related challenges. Positive Phase 2 study results could significantly enhance NeuroSense's market position and investor sentiment regarding PrimeC's potential in Alzheimer's treatment.

NeuroSense Therapeutics Ltd. is scheduled to hold a pre-New Drug Submission (NDS) meeting with Health Canada in April 2026. This meeting is a critical step in the regulatory process for the company's therapeutic products, potentially paving the way for future approvals and market entry. The pre-NDS meeting with Health Canada is a significant regulatory milestone that could influence the company's future product approvals and market positioning.

NeuroSense Therapeutics Ltd. has received FDA clearance to initiate a pivotal Phase 3 trial for its drug PrimeC, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This trial marks a significant step in the company's efforts to advance its treatment options for ALS patients, potentially impacting the future of the drug's development and market presence. FDA clearance for a pivotal Phase 3 trial represents a significant regulatory milestone that could greatly influence the company's future performance and investor sentiment.

NeuroSense Therapeutics Ltd. (NRSN) will host an investor webinar on December 8, 2025, to discuss its latest developments and future plans. The event aims to engage with investors and provide insights into the company's progress in the neurodegenerative disease space. The webinar may influence investor sentiment and provide updates on key developments, but its overall impact on the company's trajectory is expected to be limited.

NeuroSense Therapeutics Ltd. announced that its drug PrimeC has shown statistically significant reductions in Alzheimer's disease biomarkers in recent clinical trials. The results indicate potential for PrimeC to impact the treatment landscape for Alzheimer's, as the findings suggest improvements in key indicators associated with the disease. This development may enhance the company's position in the neurodegenerative disease market. Significant reductions in Alzheimer's biomarkers could lead to major advancements in treatment options and investor interest.

NeuroSense Therapeutics Ltd. reported early positive results from its drug candidate in neurons derived from Alzheimer's patients. The findings suggest potential benefits in treating the disease, indicating a promising direction for the company's research and development efforts. Early positive results in Alzheimer's research could significantly enhance the company's market position and investor sentiment.

NeuroSense Therapeutics Ltd. announced a private placement of $500,000 at a premium to its current market price. This funding aims to support the company's ongoing development efforts and enhance its financial position. The placement reflects investor confidence in NeuroSense's potential and strategic direction. The private placement may provide necessary funding for development, impacting financial performance and investor sentiment moderately.

NeuroSense Therapeutics Ltd. provided a business update highlighting progress in its clinical trials and research initiatives for the first half of 2025. The company reported advancements in its lead drug candidate for neurodegenerative diseases and outlined strategic partnerships aimed at enhancing its market position. Financial metrics showed a stable cash position, enabling continued investment in R&D. The update reflects the company's commitment to innovation and potential growth in the biotech sector. Significant advancements in clinical trials and strategic partnerships could notably enhance the company's market position and investor sentiment.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) announced the scaling up of its PrimeC production to a commercial scale, a drug candidate for ALS combining ciprofloxacin and celecoxib. The company enhanced its supply chain and partnered with a global CDMO for future commercial supply. Stability data indicates a shelf life of at least 36 months, and formulation IP protection extends to 2042. NeuroSense is pursuing early market entry in Canada, with potential peak annual revenue of $100–150 million. Analyst Jason Kolbert from D. Boral Capital initiated coverage with a Buy rating and a $14 price target, citing strong preclinical support for PrimeC. The ongoing Phase 2b PARADIGM trial is expected to report results in 2025, and NeuroSense is exploring partnerships with major pharmaceutical companies for PrimeC's development. The scaling of production and potential partnerships could significantly alter the company's trajectory and investor sentiment.